NatWest Venture Banking hires life sciences lead from HSBC
NatWest Venture Banking has appointed Emily Pilkington as Head of Life Sciences, Healthcare and Planetary Health, drawing on thirteen years of specialist lending experience across SVB, DNB, Barclays and HSBC Innovation Banking to anchor what the bank describes as a market-leading proposition for the UK's venture-backed innovation economy.
The appointment arrives four months after NatWest launched its dedicated Venture Banking unit in April, a structural reorganisation designed to compete more directly with specialist innovation lenders for the loyalty of high-growth founders and their investor networks. The team now counts more than 30 specialist bankers and is building regional coverage across the UK, offering tailored debt and capital-access services to companies from seed stage through to exit.
A talent grab with a strategic backdrop
Pilkington's move from HSBC Innovation Banking is notable in context. Silicon Valley Bank's UK arm was acquired by HSBC in March 2023 following the California parent's collapse, leaving HSBC suddenly holding the dominant market position in UK innovation lending almost overnight. NatWest's systematic recruitment of experienced venture-banking talent signals a deliberate attempt to contest that position rather than cede the innovation economy to a single incumbent.
The life sciences vertical is a logical bridgehead. UK life sciences contributed an estimated £94 billion in turnover to the economy in the most recent government figures, and the sector has been a consistent draw for both domestic and international institutional capital. For a bank competing for relationships with venture-backed scale-ups, credibility in life sciences lending is effectively table stakes, given how capital-intensive the development cycle is and how complex the covenant structures around clinical milestones can be.
The convergence angle: where banking meets deep tech
The "Planetary Health" element of Pilkington's remit is worth isolating for the cross-sector reader. The phrase signals an explicit overlap between life sciences lending and climate or environmental-biology ventures, a convergence that is drawing increasing interest from both sovereign and institutional investors. As biotech and sustainability investment theses converge around synthetic biology, bioremediation and novel materials, the banks that build specialist coverage early will be better placed to structure the more complex instruments those companies require.
Jenny Edwards, Head of NatWest Venture Banking, said: "Life sciences, healthcare and planetary sciences are areas where the UK has real strength, and Emily's deep sector experience will further enhance the specialist, flexible support we provide to founders and investors."
For the macro strategist, the broader signal here is one of incumbency risk in innovation banking. The SVB collapse removed a specialist counterparty from the market and compressed competitive pressure almost immediately. That pressure is now rebuilding as NatWest, alongside a handful of boutique lenders, moves to reconstruct a genuine multi-bank ecosystem for UK deep-tech and life sciences founders. Whether that dynamic ultimately benefits founders through better pricing and more flexible structuring, or merely replicates the single-incumbent model with a different logo, will depend heavily on whether new entrants can match specialist expertise rather than just headcount.
Pilkington's track record across the full growth lifecycle, from early-stage coverage at SVB to senior debt-finance roles at HSBC Innovation Banking, suggests NatWest has recruited for depth rather than breadth. The next signal to watch is the composition of the deal flow that the unit actually closes in the next two to three quarters.